 |
|
|
||||||||||||||
 |
|
|
Tethys Bioscience Joins National Diabetes Goal
2008-Nov-20 — Company joins national move to ensure Americans know their risk of developing Type 2 Diabetes.
Emeryville, CA (November 19, 2008) - Tethys Bioscience, Inc. has joined more than 37 national organizations and companies to become a National Diabetes Goal Champion. The National Diabetes Goal is an effort by organizations, trade associations, and corporations to help reduce the number of type 2 diabetes cases in the United States.
The Goal seeks to ensure that, by 2015, 45% of Americans who are at risk (59 million adults) for type 2 diabetes will understand their individual risk and what actions to take to prevent diabetes. Today, only 17% of American adults - approximately 22 million of the more than 130 million at risk - who are at risk for diabetes actually are aware of their risk and the steps they can take to prevent the disease.
"Tethys is proud to be among the supporters of the National Diabetes Goal, which parallels the company's goal to foster diabetes prevention through personalized risk assessment", said Mickey Urdea, founder, chairman and CEO of Tethys. "We believe that preventing diabetes will result only through the integration of the medical community, industry, advocacy groups and media in a unified campaign."
Today nearly two-thirds of U.S. adults (133 million) are overweight or obese, a key risk factor for diabetes. While in 2007, the Centers for Disease Control and Prevention (CDC) conducted a study which showed that nearly 24 million people in the U.S. have diabetes - an increase of more than 3 million in two years. Additionally an estimated 57 million American adults are known to be "pre-diabetic", placing them at increased risk for adverse outcomes associated with diabetes, including retinopathy, stroke, myocardial infarction and death.
"We will support the National Diabetes Goal to maximize diabetes-risk awareness and promote prevention as we broaden availability of the PreDxTM Diabetes Risk Test in the U.S." said Mike Richey, Tethys Chief Business Officer. "The Test results in a 5-year risk score which will enable individuals and their physicians to identify their personalized risk and take action in time to prevent the disease. Our objective is to encourage Americans to understand their risk by knowing their diabetes risk score".
About the National Diabetes Goal
The National Diabetes Goal was first launched in May 2008 by the National Changing Diabetes Program (NCDP) in conjunction with many healthcare stakeholders, including, among others the American Diabetes Association and the American Association of Diabetes Educators.
About Tethys Bioscience
Tethys Bioscience is a predictive personalized medicine company developing novel tests which address the growing global healthcare challenge of chronic diseases such as diabetes. Founded in 2005, the company integrates an experienced management team, innovative research based on sound science, a CLIA-licensed clinical laboratory, and a commercialization team with extensive experience in diagnostic innovation. Our partnerships with world class researchers and our solid financial foundation will enable Tethys to help transform the management of chronic diseases by providing personalized, preventive solutions that aid every constituency: patients, doctors and the healthcare system as a whole.
# # #
< Back
Jul 22, 2010
Tethys Raises $33 Million
Tethys Bioscience, Inc., announced today that the company has recently raised $33 million, comprising $23 million of venture financing and a $10 million working capital loan.
Jul 14, 2010
Diabetes Risk, on a Scale of 1 to 10
A new test is transforming the way some doctors diagnose and treat their patients.
(Technology Review)
Jul 1, 2010
PreDx® featured on CBS Interactive's Smartplanet
CBS Interactive smartplanet video segment focuses on the impact of the PreDx® Diabetes Risk Score on the physician and patient.
Jun 24, 2010
Tethys Announces Issuance of Key Patent Relating to PreDx™ Diabetes Risk Score Test
United States Patent and Trademark Office grants patent to Tethys. The patent is directed to the company's groundbreaking PreDx™ Diabetes Risk Score (DRS) test and relates to proprietary methods for assessing the risk of developing a diabetic condition.
Nov 9, 2009
Tethys Bioscience Raises $25 Million in Series D Financing
The financing round is led by aeris Capital with George Rehm taking a seat on the Tethys board.
Oct 20, 2009
Gazing into the Future
(Journal of Life Sciences, Fall 2009)